Key result
Long-term survivors of childhood Hodgkin disease treated with doxorubicin had a significantly greater myocardial performance index compared to healthy controls (P=0.0001).
Why the study?
Does prior doxorubicin treatment for childhood Hodgkin disease cause long-term echocardiographic abnormalities (measured by myocardial performance index) compared to healthy controls?
Case-Control (n=53)
Does prior doxorubicin treatment for childhood Hodgkin disease cause long-term echocardiographic abnormalities (measured by myocardial performance index) compared to healthy controls?
Myocardial performance index (MPI) can detect subtle, long-term systolic and diastolic cardiac abnormalities in the majority of childhood Hodgkin disease survivors treated with doxorubicin.
MPI may flag subclinical dysfunction in doxorubicin-treated Hodgkin survivors; leaves open its prognostic value for surveillance.
BACKGROUND: Data on the presence of myocardial abnormalities in long-term Hodgkin disease survivors are contradictory. The purpose of this study was to determine if myocardial performance index (MPI) was capable of discovering cardiac abnormalities. PROCEDURE: Echocardiographic evaluation was performed in 31 survivors of Hodgkin disease (mean age 17.0 years), who received doxorubicin as part of chemotherapeutic treatment (median dose 164.8 +/- 42.5 mg/m(2)). Control group comprised 22 healthy subjects (mean age 16.7 years). RESULTS: Peak A velocity was increased (P = 0.004) and peak E/A velocity ratio was lower (P = 0.002) in patients compared to controls. Mean isovolumetric contraction time was longer in patients than in controls (P = 0.0001). Ejection time was significantly shorter in patients than in the controls (P = 0.001). Consequently, the MPI was significantly greater in the patients than in the controls (P = 0.0001). Abnormal MPI was found in 25/31 patients (83%). CONCLUSIONS: The Doppler-derived index of combined systolic and diastolic myocardial performance demonstrates the presence of subtle cardiac abnormalities in the majority of Hodgkin disease survivors.
No takes yet. Share an insight, caveat, or question.
Iarussi et al. (2005) conducted a case-control in Childhood Hodgkin disease (n=53). Childhood Hodgkin disease treated with doxorubicin vs. Healthy subjects was evaluated on Myocardial performance index (MPI) (p=0.0001). Long-term survivors of childhood Hodgkin disease treated with doxorubicin had a significantly greater myocardial performance index compared to healthy controls (P=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: